Back to Search Start Over

Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.

Authors :
Qian H
Yang X
Zhang T
Zou P
Zhang Y
Tian W
Mao Z
Wei J
Source :
American journal of hematology [Am J Hematol] 2024 Apr; Vol. 99 (4), pp. 662-678. Date of Electronic Publication: 2024 Jan 10.
Publication Year :
2024

Abstract

Chimeric antigen receptor (CAR) T-cell therapy, an innovative immunotherapeutic against relapsed/refractory B-cell lymphoma, faces challenges due to frequent viral infections. Despite this, a comprehensive review addressing risk assessment, surveillance, and treatment management is notably absent. This review elucidates immune response compromises during viral infections in CAR-T recipients, collates susceptibility risk factors, and deliberates on preventive strategies. In the post-pandemic era, marked by the Omicron variant, new and severe threats to CAR-T therapy emerge, necessitating exploration of preventive and treatment measures for COVID-19. Overall, the review provides recommendations for viral infection prophylaxis and management, enhancing CAR-T product safety and recipient survival.<br /> (© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)

Details

Language :
English
ISSN :
1096-8652
Volume :
99
Issue :
4
Database :
MEDLINE
Journal :
American journal of hematology
Publication Type :
Academic Journal
Accession number :
38197307
Full Text :
https://doi.org/10.1002/ajh.27198